Knight Therapeutics Рентабельность капитала
Что обозначает Рентабельность капитала в Knight Therapeutics?
Рентабельность капитала Knight Therapeutics, Inc. является -2.75%
Какое определение для Рентабельность капитала?
Рентабельность собственного капитала является мерой доходности бизнеса по отношению к балансовой стоимости акционерного капитала. Он рассчитывается путем деления чистого дохода финансового года на общий акционерный капитал.
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Рентабельность капитала компаний в Health Care сектор на TSX по сравнению с Knight Therapeutics
Что делает Knight Therapeutics?
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Bijuva for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uterus; IMVEXXY to treat postmenopausal moderate to severe dyspareunia; IBSRELA for the treatment of irritable bowel syndrome with constipation in adults; TRELSTAR to treat advanced prostate cancer and for pain associated with endometriosis; ILUVIEN for the treatment of vision loss due to diabetic macular oedema; and NERLYNX to treat early-stage breast cancer. The company also provides Burinex, for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome; PROBUPHINE, to treat opioid addiction; and MOVANTIK for the treatment of opioid-induced constipation. In addition, it offers Vidaza to treat myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven to treat advanced or metastatic breast cancer; Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma; Ladevina to treat multiple myeloma; Zyvalix for metastatic prostate cancer; Karfib to treat relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; AmBisome and Cresemba to treat fungal infection; and Impavido for leishmaniasis. Further, the company provides Ursofalk to treat biliary cirrhosis; Salofalk for ulcerative colitis; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Компании с рентабельность капитала похож на Knight Therapeutics
- Compumedics имеет Рентабельность капитала из -2.77%
- Artini имеет Рентабельность капитала из -2.77%
- Ncino имеет Рентабельность капитала из -2.77%
- China Kangda Food имеет Рентабельность капитала из -2.76%
- Narayana Hrudayalaya имеет Рентабельность капитала из -2.76%
- medical columbus AG имеет Рентабельность капитала из -2.76%
- Knight Therapeutics имеет Рентабельность капитала из -2.75%
- Lawreshwar Polymers имеет Рентабельность капитала из -2.75%
- Nanogate SE имеет Рентабельность капитала из -2.75%
- Nanogate AG имеет Рентабельность капитала из -2.75%
- Tianda Pharmaceuticals имеет Рентабельность капитала из -2.74%
- JK Tyre & Industries имеет Рентабельность капитала из -2.74%
- Vardhman Special Steels имеет Рентабельность капитала из -2.73%